Day: August 4, 2025

Quarter-over-quarter and year-over-year revenue growth Providing guidance for accelerated revenue growth in the third quarter MIGDAL HAEMEK, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ/TASE: TSEM) reports today its results for the second quarter ended June 30, 2025. Second Quarter of 2025 Results Overview Revenues for the second quarter of 2025 were $372 million, representing revenue growth of 6% year-over-year and 4% quarter-over-quarter. Gross profit for the second quarter of 2025 was $80 million, compared to $73 million in the first quarter of 2025. Net profit for the second quarter of 2025 was $47 million, reflecting $0.42 basic and $0.41 diluted earnings per share. First quarter of 2025 net profit was $40 million, reflecting $0.36 basic and $0.35 diluted earnings per share. Cash flow generated from...

Municipality Finance PlcHalf Year Report4 August 2025 at 2:00 pm (EEST) MuniFin Group’s Half Year Report January–June 2025 is published This release is a summary of MuniFin Group’s Half Year Report published on 4 August 2025. The complete Half Year Report with tables is attached to this release and available at www.munifin.fi. MuniFin Group will also publish its Pillar III Half Year Disclosure Report 2025 in accordance with Regulation (EU) No 575/2013 and Directive 2013/36/EU during the calendar week 33. The report will be available at MuniFin’s website. In brief: MuniFin Group in the first half of 2025The Group’s net operating profit excluding unrealised fair value changes* decreased by 11.9% (+9.6%) in January–June and amounted to EUR 79 million (EUR 89 million). Net interest income* fell by 3.6% (+3.4%) and totalled EUR 124 million...

Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 – $575 million Conference call to be held today, Monday, August 4, 2025, at 8:30 AM ET    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2025, along with recent company developments, and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We’re incredibly proud of the continued momentum behind BRIUMVI, which we believe is establishing itself as a leading anti-CD20 therapy in adults with relapsing MS. The strong uptake we’re seeing, combined...

ALMATY, Kazakhstan, Aug. 04, 2025 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”) (Nasdaq:KSPI) which operates the Kaspi.kz and Kaspi Pay Super Apps in Kazakhstan and owns 66.35% of Hepsiburada in Türkiye, today published its unaudited consolidated IFRS financial results for the quarter and first half ended 30 June 2025 (“2Q & 1H 2025”). 2Q & 1H 2025 Highlights2Q 2025 revenue up 20% year-over-year (“YoY”) and net income up 14% YoY. For 1H 2025 revenue and net income up 20% and 15% YoY respectively. This and all references below exclude Türkiye unless otherwise stated. Customer engagement remains strong with Monthly Transactions per Active Consumer at 75. In Payments, operational gearing once again resulted in profit growth ahead of revenue growth.Payments TPV and transactions up 21% and 14% YoY,...

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million new covered lives in the commercial channel First group purchasing organization (GPO) contract for SYMBRAVO® signed Supplemental NDA submission for AXS-05 in Alzheimer’s disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 4Q 2025 Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug....

$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update. “With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “At the same time, we are rapidly approaching key readouts in both the lung and eye. Success in these tissues would be transformational...

—Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— —Company makes additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds of sale of European ORLADEYO business— RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. “The financial performance this quarter is the best in the company’s history resulting from better-than-expected revenue growth and very meaningful operating profit. In the fifth year since approval, ORLADEYO revenue and demand have never been stronger, and this is...